Total Payments
$263,651
2024 Payments
$69,138
Companies
71
Transactions
1,617
Medicare Patients
27,781
Medicare Billing
$1.6M
Payment Breakdown by Category
Other$109,985 (41.7%)
Research$82,064 (31.1%)
Consulting$39,018 (14.8%)
Food & Beverage$23,975 (9.1%)
Travel$8,264 (3.1%)
Education$344.89 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $89,154 | 71 | 33.8% |
| Unspecified | $82,064 | 20 | 31.1% |
| Consulting Fee | $39,018 | 39 | 14.8% |
| Food and Beverage | $23,975 | 1,421 | 9.1% |
| Honoraria | $16,770 | 12 | 6.4% |
| Travel and Lodging | $8,264 | 19 | 3.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,997 | 4 | 1.1% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $1,014 | 3 | 0.4% |
| Education | $344.89 | 27 | 0.1% |
| Long term medical supply or device loan | $49.95 | 1 | 0.0% |
Payments by Type
General
$181,587
1,597 transactions
Research
$82,064
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $81,644 | 18 | $0 (2024) |
| Corcept Therapeutics | $59,348 | 127 | $0 (2024) |
| Novo Nordisk Inc | $41,402 | 241 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $35,551 | 139 | $0 (2024) |
| PFIZER INC. | $9,679 | 22 | $0 (2024) |
| Esperion Therapeutics, Inc. | $6,651 | 16 | $0 (2024) |
| Dexcom, Inc. | $5,742 | 12 | $0 (2023) |
| Insulet Corporation | $4,662 | 30 | $0 (2024) |
| Tandem Diabetes Care, Inc. | $3,315 | 27 | $0 (2024) |
| Lilly USA, LLC | $1,901 | 158 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $69,138 | 170 | Eli Lilly and Company ($35,760) |
| 2023 | $37,002 | 193 | Novo Nordisk Inc ($11,178) |
| 2022 | $14,546 | 157 | Novo Nordisk Inc ($7,335) |
| 2021 | $23,306 | 192 | AstraZeneca Pharmaceuticals LP ($7,427) |
| 2020 | $28,897 | 175 | AstraZeneca Pharmaceuticals LP ($15,153) |
| 2019 | $21,819 | 251 | Corcept Therapeutics ($9,862) |
| 2018 | $47,836 | 231 | Eli Lilly and Company ($30,123) |
| 2017 | $21,107 | 248 | Eli Lilly and Company ($11,713) |
All Payment Transactions
1,617 individual payment records from CMS Open Payments — Page 1 of 65
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $2.39 | General |
| Category: Diabetes Care | ||||||
| 12/27/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: Diabetes Care | ||||||
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: DIABETES | ||||||
| 12/13/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: Endocrinology | ||||||
| 12/12/2024 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Insulin Pump | ||||||
| 12/11/2024 | Corcept Therapeutics | Korlym (Drug) | Consulting Fee | Cash or cash equivalent | $655.00 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $22.16 | General |
| 12/10/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: Diabetes Care | ||||||
| 12/06/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $33.07 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/06/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 12/05/2024 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Endocrinology | ||||||
| 12/04/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/26/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: Diabetes | ||||||
| 11/22/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Obesity | ||||||
| 11/22/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: DIABETES | ||||||
| 11/19/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Diabetes | ||||||
| 11/14/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,437.50 | General |
| Category: Obesity | ||||||
| 11/14/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $115.76 | General |
| Category: Obesity | ||||||
| 11/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: Cardio-renal | ||||||
| 11/12/2024 | Eli Lilly and Company | — | — | In-kind items and services | $1.62 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | ||||||
| 11/06/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: Diabetes Care | ||||||
| 10/31/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,843.75 | General |
| Category: Obesity | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: Cardiovascular and Metabolism | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $41,836 | 3 |
| A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (TRANSCEND-T2D-1) | Eli Lilly and Company | $27,235 | 2 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $8,830 | 3 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $1,963 | 3 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $863.09 | 1 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF INVESTIGATIONAL TIRZEPATIDE DOSES IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY | Eli Lilly and Company | $527.07 | 1 |
| NN143-4625 | Novo Nordisk AS | $420.00 | 2 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $268.58 | 1 |
| A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $50.00 | 1 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $50.00 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | Eli Lilly and Company | $19.30 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | Eli Lilly and Company | $1.62 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 6,086 | 16,458 | $1.1M | $394,397 |
| 2022 | 38 | 7,015 | 42,702 | $1.2M | $439,538 |
| 2021 | 43 | 7,326 | 51,081 | $1.2M | $442,302 |
| 2020 | 40 | 7,354 | 54,539 | $1.1M | $372,804 |
Total Patients
27,781
Total Services
164,780
Medicare Billing
$1.6M
Procedure Codes
154
All Medicare Procedures & Services
154 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 70 | 7,200 | $237,600 | $131,712 | 55.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 508 | 711 | $202,635 | $86,495 | 42.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 473 | 614 | $128,940 | $50,257 | 39.0% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 312 | 318 | $89,040 | $24,801 | 27.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 679 | 1,082 | $64,920 | $17,773 | 27.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 828 | 1,378 | $34,450 | $11,575 | 33.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 604 | 960 | $57,600 | $9,920 | 17.2% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 596 | 948 | $47,400 | $8,347 | 17.6% |
| 82306 | Vitamin d-3 level | Office | 2023 | 204 | 262 | $19,650 | $7,580 | 38.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 142 | 274 | $29,592 | $6,970 | 23.6% |
| 84481 | Thyroid hormone, t3 measurement, free | Office | 2023 | 253 | 367 | $22,020 | $6,055 | 27.5% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 325 | 550 | $19,250 | $5,229 | 27.2% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 177 | 306 | $13,770 | $4,015 | 29.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 36 | 36 | $11,520 | $4,001 | 34.7% |
| 84403 | Testosterone (hormone) level, total | Office | 2023 | 63 | 120 | $12,120 | $3,035 | 25.0% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 59 | 73 | $5,110 | $2,953 | 57.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 80 | 225 | $12,600 | $2,105 | 16.7% |
| 82533 | Cortisol (hormone) measurement, total | Office | 2023 | 69 | 105 | $5,565 | $1,677 | 30.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 24 | $3,696 | $1,444 | 39.1% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 142 | 238 | $4,760 | $1,347 | 28.3% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 142 | 238 | $8,330 | $1,209 | 14.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 81 | 139 | $5,560 | $1,058 | 19.0% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 22 | 22 | $6,138 | $780.78 | 12.7% |
| 82627 | Dehydroepiandrosterone (dhea-s) hormone level | Office | 2023 | 21 | 29 | $1,740 | $631.91 | 36.3% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 25 | 40 | $1,800 | $591.20 | 32.8% |
About Dr. John Parker, M.D
Dr. John Parker, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Wilmington, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1457345928.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Parker, M.D has received a total of $263,651 in payments from pharmaceutical and medical device companies, with $69,138 received in 2024. These payments were reported across 1,617 transactions from 71 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($89,154).
As a Medicare-enrolled provider, Parker has provided services to 27,781 Medicare beneficiaries, totaling 164,780 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 154 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Wilmington, NC
- Active Since 09/09/2005
- Last Updated 02/08/2021
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1457345928
Products in Payments
- Korlym (Drug) $59,348
- FARXIGA (Drug) $35,376
- Wegovy (Drug) $31,925
- Saxenda (Drug) $7,644
- Dexcom CGM (Device) $5,661
- NEXLIZET (Drug) $5,151
- Omnipod (Device) $4,662
- t-slim insulin pump (Device) $3,162
- JARDIANCE (Drug) $1,782
- NEXLETOL (Drug) $1,500
- Ozempic (Drug) $1,074
- EVENITY (Biological) $700.89
- Strensiq (Drug) $611.13
- HUMULIN (Drug) $607.35
- JANUVIA (Drug) $574.05
- Repatha (Biological) $494.84
- Kerendia (Drug) $479.58
- FREESTYLE LIBRE 3 (Device) $445.97
- SOLIQUA 100/33 (Biological) $410.79
- XYOSTED (Drug) $390.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Wilmington
Dr. Michael Favorito, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $835,998
Endocrinology, Diabetes & Metabolism $835,998
Seth Braunstein, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $302,990
Endocrinology, Diabetes & Metabolism $302,990
William Jaffee, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $30,425
Endocrinology, Diabetes & Metabolism $30,425
Dr. Lauren Gratian, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $18,266
Endocrinology, Diabetes & Metabolism $18,266
Michael Mcgarrity, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $14,550
Endocrinology, Diabetes & Metabolism $14,550
Prakash Seshadri, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $6,152
Endocrinology, Diabetes & Metabolism $6,152